X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Lasix-Generic (furosemide) is a USFDA approved loop diuretic, which is indicated for the treatment of adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lasix-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
Furoscix (furosemide injection) is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
Furoscix® is a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
Furoscix® is a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Furoscix® (furosemide) primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
FUROSCIX® (furosemide injection) is a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 21, 2022
Details:
FUROSCIX® (furosemide injection) is a drug product indicated for the treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II/III chronic heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Brand Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
scPharmaceuticals plans to use funds, together with cash on-hand, to repay indebtedness under its existing loan and security agreement and to execute on the launch of FUROSCIX (furosemide), which received marketing approval from the U.S. FDA.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 10, 2022
Details:
FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for treatment of congestion,demonstrated 99.6% bioavailability and 8-hour urine output of 2.7 L which was similar to subjects receiving intravenous furosemide.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
Subject randomized to FUROSCIX (furosemide 80 mg/10 mL for subcutaneous administration), had a 37% reduction in the risk of a heart failure hospitalization relative to patients randomized to “treatment as usual” at day 30.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
FUROSCIX (furosemide), a proprietary formulation of furosemide that is designed to be administered by subcutaneous infusion via a wearable, pre-programmed on-body, drug delivery system.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
FUROSCIX (furosemide) is an investigational, proprietary furosemide solution formulated to a neutral pH, designed to allow for subcutaneous infusion via a wearable, pre-programmed on-body drug delivery system, for outpatient self-administration.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
FUROSCIX (Furosemide) is an investigational, proprietary furosemide solution formulated to a neutral pH, designed to allow for subcutaneous infusion via a wearable, pre-programmed on-body drug delivery system, for outpatient self-administration.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
FUROSCIX is an investigational, proprietary furosemide solution formulated to a neutral pH, designed to allow for subcutaneous infusion via a wearable, pre-programmed on-body drug delivery system, for outpatient self-administration.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2021
Details:
The scPharmaceuticals management team will discuss the FUROSCIX® development plan. FUROSCIX® is an investigational, proprietary formulation of furosemide that is administered subcutaneously via a wearable on-body, drug delivery system, for outpatient self-administration.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
scPharmaceuticals is developing FUROSCIX, a proprietary, subcutaneously delivered furosemide solution, as an outpatient alternative for the treatment of worsening heart failure due to congestion.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
scPharmaceuticals has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of FUROSCIX® (subcutaneous furosemide) for the treatment of congestion in patients with heart failure.
Lead Product(s): Furosemide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Furoscix
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
